These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1178 related articles for article (PubMed ID: 23209033)
1. The definition of primary and secondary glioblastoma. Ohgaki H; Kleihues P Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033 [TBL] [Abstract][Full Text] [Related]
2. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Nobusawa S; Watanabe T; Kleihues P; Ohgaki H Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the IDH1 codon 132 mutation in brain tumors. Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363 [TBL] [Abstract][Full Text] [Related]
4. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772 [TBL] [Abstract][Full Text] [Related]
5. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
6. Genetic pathways to primary and secondary glioblastoma. Ohgaki H; Kleihues P Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751 [TBL] [Abstract][Full Text] [Related]
7. MET gain in diffuse astrocytomas is associated with poorer outcome. Pierscianek D; Kim YH; Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Wrede K; Nakazato Y; Tanaka Y; Mariani L; Vital A; Sure U; Ohgaki H Brain Pathol; 2013 Jan; 23(1):13-8. PubMed ID: 22672415 [TBL] [Abstract][Full Text] [Related]
8. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Ichimura K; Pearson DM; Kocialkowski S; Bäcklund LM; Chan R; Jones DT; Collins VP Neuro Oncol; 2009 Aug; 11(4):341-7. PubMed ID: 19435942 [TBL] [Abstract][Full Text] [Related]
9. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Watanabe T; Nobusawa S; Kleihues P; Ohgaki H Am J Pathol; 2009 Apr; 174(4):1149-53. PubMed ID: 19246647 [TBL] [Abstract][Full Text] [Related]
10. Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma. Hata N; Suzuki SO; Murata H; Hatae R; Akagi Y; Sangatsuda Y; Amano T; Yoshimoto K; Tahira T; Mizoguchi M Pathol Oncol Res; 2015 Jul; 21(3):839-43. PubMed ID: 25354913 [TBL] [Abstract][Full Text] [Related]
11. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932 [TBL] [Abstract][Full Text] [Related]
12. Genetic profile of astrocytic and oligodendroglial gliomas. Ohgaki H; Kleihues P Brain Tumor Pathol; 2011 Jul; 28(3):177-83. PubMed ID: 21442241 [TBL] [Abstract][Full Text] [Related]
13. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
14. Phenotype vs genotype in the evolution of astrocytic brain tumors. Kleihues P; Ohgaki H Toxicol Pathol; 2000; 28(1):164-70. PubMed ID: 10669004 [TBL] [Abstract][Full Text] [Related]
15. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Ohgaki H; Kleihues P J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639 [TBL] [Abstract][Full Text] [Related]
16. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261 [TBL] [Abstract][Full Text] [Related]
17. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362 [TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations in primary and secondary glioblastomas. Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565 [TBL] [Abstract][Full Text] [Related]
19. PDGFRA gain in low-grade diffuse gliomas. Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Nonoguchi N; Pierscianek D; Kim YH; Mariani L; Vital A; Perry A; Ohgaki H J Neuropathol Exp Neurol; 2013 Jan; 72(1):61-6. PubMed ID: 23242283 [TBL] [Abstract][Full Text] [Related]
20. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]